Eli Lilly and Company (LLY)vsU.S. Physical Therapy, Inc. (USPH)
LLY
Eli Lilly and Company
$1,208.12
+7.13%
HEALTHCARE · Cap: $1.08T
USPH
U.S. Physical Therapy, Inc.
$66.32
+2.72%
HEALTHCARE · Cap: $1.05B
Smart Verdict
WallStSmart Research — data-driven comparison
Eli Lilly and Company generates 9072% more annual revenue ($72.25B vs $787.68M). LLY leads profitability with a 35.0% profit margin vs 4.4%. LLY appears more attractively valued with a PEG of 1.46. LLY earns a higher WallStSmart Score of 78/100 (B+).
LLY
Strong Buy78
out of 100
Grade: B+
USPH
Buy52
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for LLY.
Margin of Safety
-2.6%
Fair Value
$85.88
Current Price
$66.32
$19.56 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 81 in profit
Keeps 35 of every $100 in revenue as profit
Strong operational efficiency at 49.4%
Revenue surging 55.5% year-over-year
Earnings expanding 169.9% YoY
Reasonable price relative to book value
Earnings expanding 23.6% YoY
Areas to Watch
Elevated debt levels
Premium valuation, high expectations priced in
Trading at 34.6x book value
Expensive relative to growth rate
Smaller company, higher risk/reward
ROE of 0.3% — below average capital efficiency
4.4% margin — thin
Comparative Analysis Report
WallStSmart ResearchBull Case : LLY
The strongest argument for LLY centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 35.0% and operating margin at 49.4%. Revenue growth of 55.5% demonstrates continued momentum.
Bull Case : USPH
The strongest argument for USPH centers on Price/Book, EPS Growth.
Bear Case : LLY
The primary concerns for LLY are Debt/Equity, P/E Ratio, Price/Book. A P/E of 42.9x leaves little room for execution misses.
Bear Case : USPH
The primary concerns for USPH are PEG Ratio, Market Cap, Return on Equity. A P/E of 137.6x leaves little room for execution misses. Thin 4.4% margins leave little buffer for downturns.
Key Dynamics to Monitor
LLY profiles as a growth stock while USPH is a value play — different risk/reward profiles.
USPH carries more volatility with a beta of 1.16 — expect wider price swings.
LLY is growing revenue faster at 55.5% — sustainability is the question.
LLY generates stronger free cash flow (3.0B), providing more financial flexibility.
Bottom Line
LLY scores higher overall (78/100 vs 52/100), backed by strong 35.0% margins and 55.5% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Eli Lilly and Company
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.
Visit Website →U.S. Physical Therapy, Inc.
HEALTHCARE · MEDICAL CARE FACILITIES · USA
US Physical Therapy, Inc. operates outpatient physical therapy clinics that provide preoperative and postoperative care and treatment for orthopedic-related disorders, sports-related injuries, preventive care, injured worker rehabilitation, and neurology-related injuries. The company is headquartered in Houston, Texas.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?